FDA Grants Final Approval for Eugia US's Tranexamic Acid Generic Injectable ANDA
FDA Approves Eugia US's Tranexamic Acid Injectable Generic
The FDA has granted final approval for ANDA 205035, the tranexamic acid generic injectable from Eugia US LLC, a subsidiary of Aurobindo Pharma. This approval demonstrates bioequivalence to the reference listed drug, Cyklokapron from Pfizer, and marks a significant step towards market entry. Tranexamic acid reversibly binds to the lysine binding site of plasminogen, inhibiting fibrinolysis. With this approval, Eugia US further strengthens its position in the U.S. essential medicines supply chain.
Preventing Bleeding in Hemophilia Patients and Clinical Significance
This drug is primarily used to reduce and prevent short-term bleeding that may occur in hemophilia patients undergoing dental extraction procedures. Hemophilia patients are at high risk of severe bleeding even from minor surgeries, making antifibrinolytic agents, which reversibly block fibrin breakdown, crucial. Clinically, this injectable is administered for 2 to 8 days before and after surgery, significantly reducing the need for blood replacement therapy in patients. This provides direct clinical benefits by reducing reliance on expensive factor replacement therapy and alleviating the financial burden on patients.
Tranexamic Acid Market Size and Eugia's Competitiveness
The global market for tranexamic acid active pharmaceutical ingredients (APIs) and finished products is estimated at $776.9 million in 2025 and is expected to grow steadily at an annual rate of 4.4%. Eugia US, headquartered in New Jersey, has a portfolio specializing in generic injectable manufacturing and distribution, giving it a strong advantage in direct sales channels to hospitals and healthcare institutions. In the U.S. injectable market, where numerous generic competitors, including the original manufacturer Pfizer, Fresenius Kabi, and Hikma, have already established a presence, Eugia plans to secure market share based on its cost competitiveness. In particular, it holds high value as a stable supply source in the U.S. healthcare system, which suffers from chronic essential medicine shortages.
Securing Growth Momentum for Parent Company Aurobindo Pharma
This regulatory approval can be seen as part of Aurobindo Pharma's strategy to diversify its specialty generic and injectable portfolios in the U.S. market. Meeting the FDA's stringent sterile manufacturing standards and obtaining generic approval demonstrates Eugia's manufacturing quality and regulatory compliance capabilities. The synergy between the parent company's local finished product manufacturing facilities in India and Eugia's U.S. distribution capabilities is expected to contribute to revenue diversification in the future. This will enhance the profitability of the specialty pharmaceuticals segment and serve as an important milestone in strengthening Aurobindo's long-term global growth.
The approval of Eugia US's tranexamic acid generic injectable (ANDA 205035) will serve as a short-term catalyst for Aurobindo Pharma's U.S. injectable business growth in the $776.9 million global market. It creates an opportunity to secure generic market share by inducing price competition with existing market oligopolists such as Pfizer, the originator of Cyklokapron, and Fresenius Kabi. From a research and regulatory perspective, it demonstrates compliance with the FDA's sterile injectable manufacturing quality standards (cGMP), significantly reducing the risk of delays in approvals for subsequent generic pipelines that Eugia develops. In the medium to long term, it will secure an alternative supply source in the chronic U.S. injectable supply shortage market, creating public health and commercial synergies by reducing the cost of surgical bleeding management for hemophilia patients.
Source: openFDA (api_fda)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=ANDA205035